Cardiome Pharma Corp. Announces Final Results of Te...(ncluding common shares deposited at pric...),Health

Date:10/16/2009

ncluding common shares deposited at prices greater than the Purchase Price and common shares not purchased because of pro-ration or because the tendering shareholder's minimum conditional tender conditions were not met, will be returned to shareholders as promptly as possible.

Oppenheimer & Co. and Canaccord Capital Corporation (the "Dealer Managers") served as dealer managers for the Offer in the United States and Canada, respectively, and Computershare Investor Services, Inc. (the "Depository") acted as depository.

About Cardiome Pharma Corp.

Cardiome Pharma Corp. is a product-focused drug development company dedicated to the advancement and commercialization of novel treatments for disorders of the heart and circulatory system. Cardiome is traded on the NASDAQ Global Market (CRME) and the Toronto Stock Exchange (COM). For more information, please visit our web site at www.cardiome.com.

Forward-Looking Statement Disclaimer

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments expressed or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of product revenues, additional capital requirements, risk associated with the completion of clinical tr
'/>"/>

SOURCE Cardiome Pharma Corp. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine news :

1. Cardiome Pharma Corp. Announces Commencement of US$27.5 Million Tender Offer
2. Cardiome Announces Upcoming Presentation Of Results Of Phase 2b Clinical Trial Of Vernakalant (Oral) At The European Society Of Cardiology Congress 2009
3. Cardiome Pharma Corp. Announces Tender Offer To Purchase Up To US$27.5 Million Of Its Common Shares
4. Atherotech Adds New Cardiometabolic Tests Amid Strong 2009 Growth
5. Cardiome to Hold Conference Call
6. Cardiome Announces Management Transition
7. Cardiome Achieves Milestone From Collaboration With Merck Co., Inc.
8. Cardiome Announces That Collaboration and License Agreement with Merck & Co., Inc. Now Effective
9. Cardiome Reports First Quarter Results
10. Cardiome to Hold Conference Call
11. CardioCareLive.com, First Ever Online Cardiometabolic Conference, Revolutionizes Continuing Medical Education for Cardiovascular Healthcare Professionals